Irrational exuberance could evaporate quickly

COMMENT; `Whatever popular measures Mr Brown announces to help young people into work or boost families on low incomes, the bottom line as far as the City is concerned will be the net increase in the tax burden compared with last November's Budget'

Has irrational exuberance finally crossed to this side of the Atlantic? The stock market yesterday made its biggest one-day gain since the crash of 1987. The driving force was the expectation that Gordon "Irn- Bru" Brown will deliver a tough, tax-raising Budget that will also contain special measures to help business. It is hard to recall when business and the City last called for tax increases, but that seems to be what they want this time round. Consumers to suffer? Hurrah, say the markets.

Whatever popular measures Mr Brown announces to help young people into work or boost families on low incomes, the bottom line as far as the City is concerned will be the net increase in the tax burden compared with last November's Budget. If it looks as if that burden is going to fall on consumer spending rather than companies, then that's good news, the markets figure.

The reckoning is that if this tax increase exceeds, say, pounds 5bn, there will be less need or excuse for the Bank of England to raise interest rates again. Most of the City is firmly convinced that it is the expectation of rising base rates that accounts for the uncomfortably strong pound. The theory is that if rates do not need to climb much further because tax hikes can head off a boom, then the pound will stop climbing too. This argument makes a few questionable assumptions. For one thing, the level of base rates is only one possible explanation for the strong pound, and it might therefore stay strong even if the prospects for UK interest rates change.

For another, it takes a net pounds 10bn rise in taxes to do the same cooling work as a 1 percentage point rise in base rates, according to most economic models. It would take at least this much tightening in policy to return the economy to a steady path. It is just about possible that Mr Brown would be prepared to add this much to the personal sector's tax bill, but it would be an extraordinary turnaround from Labour's manifesto.

Even so, the markets are probably right to anticipate a tighter Budget than anybody expected at first. On the other hand, they are equally likely to be overdoing it. Yesterday's high expectations may well be disappointed today. Similarly, the expectation that base rates will peak at a level below 7.5 per cent and stay there, implied by the short sterling futures market, is also likely to be disappointed in the longer run. Even in the best inflation environment since the 1960s, the business cycle peak for interest rates will almost certainly be higher. When that realisation sinks in, the exuberance could evaporate rather swiftly.

Merger should be good for Amersham's health

Amersham International is a curious company. Most people have heard of it, but hardly anyone outside the City and the medical profession knows what it actually does. Even fewer can tell you the purpose of what it does. It was also the previous government's first privatisation, and if you've held the shares since the beginning, you would have done spectacularly well.

Now it's merging with Nycomed of Norway to create the world's largest supplier of in-vivo diagnostic imaging agents. This is the highly specialist but, in parts, fast-growing business of supplying hospitals with chemical agents, some of them radioactive, that assist in medical diagnosis. Well, all right. Let's start again. It's the business of... Oh, forget it. Amersham helps doctors find out what's wrong with you. Let's leave it at that.

Despite doubts, this is probably a good deal for Amersham. Bill Castell, chief executive, has been pursuing it for some years and together with the recently announced link-up with Pharmacia & Upjohn, it completes a carefully planned assent into a world leading position in these markets. Amersham is still the smaller of the two companies, but in recent years it has been far more successful.

By contrast, Nycomed, operating at the maturer end of the market, has had a troubled few years. Though this is no rescue takeover, Amersham is certainly ending up with a much larger share of the action - 47 per cent - than it could have hoped for when Mr Castell first began to run his slide rule over the company a few years back. It also seems to be getting the more important executive jobs, so much so that the deal could almost be characterised as a reverse takeover by Amersham.

Doubts none the less remain. Is Amersham reversing into a dog? The pounds 40m of annual cost savings anticipated from the merger could easily be wiped out should Nycomed lose a couple of big Health Management Organisation contracts in the US that come up for renewal over the next six months. However, both companies seem to have some promising new products and applications in the pipeline. Both companies are also in the hyper trendy field of providing alternatives to invasive surgery, thus offering the prospect of real reductions in health care costs. The fact that they complement each other geographically is an added bonus. So although Nycomed Amersham will probably remain, for most people at least, a deeply obscure company, it looks destined to carry on quietly earning its shareholders an excellent return.

No easy way to resolve Anglo-French standoff

What does Bernard Arnault, the mercurial head of France's LVMH, really want? George Bull and Tony Greener, chairman of Grand Met and Guinness respectively, are flying to Paris today, hoping to find out. All they know for sure is that he doesn't approve of the planned merger of the two companies, so much so that he's spent nearly pounds 1bn stake building in Grand Met and has launched an all-out legal assault on the deal through the French courts. He also mutters inscrutably about the need to bring his own Moet Hennessy into the planned get-together. But how, and under what terms? Until he puts something on the table, it is hard to know how Grand Met and Guinness, or their shareholders, should respond.

Mr Arnault's original idea was that the Grand Met/Guinness merger should be abandoned in favour of a separate get-together of the three companies' branded drinks subsidiaries, IDV, United Distillers and Moet Hennessy. But although this might industrially seem like the sounder approach, it is hard to see how it would result in enhanced value for either Guinness or Grand Met, given that both companies would have ended up with minority holdings in the new super-drinks group. That might be the way things are done in France, but even Mr Arnault must realise that Anglo Saxon investors are just not going to buy that kind of a deal.

So what does he hope to achieve? One possibility is that he is trying to lever up the price of Moet Hennessy. Let's be clear about this. He has no intention of selling outright for cash to Les Ros Bifs. That would be too much of a betrayal. But for paper, maybe. One of his newspapers in France has already speculated that Mr Arnault might end up with 45 per cent of GMG Brands. That's obviously an exaggeration, but a stake large enough to exercise control is certainly very possible.

Unfortunately, that too would have Anglo Saxon investors screaming sell orders down their phones. Mr Arnault is a brilliant and determined businessman, but can he be trusted to run GMG Brands not just in his own interests, but in those of his outside shareholders too? At this stage, it's hard to see how this Anglo-French standoff is going to be resolved.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA celebration of British elections
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Editor-in-chief - Financial Services - City, London

£60000 - £70000 per annum + benefits : Ashdown Group: A highly successful, glo...

Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Guru Careers: Management Accountant

£27 - 35k + Bonus + Benefits: Guru Careers: A Management Accountant is needed ...

Guru Careers: Project Manager / Business Analyst

£40-50k + Benefits.: Guru Careers: A Project Manager / Business Analyst is nee...

Day In a Page

General Election 2015: ‘We will not sit down with Nicola Sturgeon’, says Ed Balls

'We will not sit down with Nicola Sturgeon'

In an exclusive interview, Ed Balls says he won't negotiate his first Budget with SNP MPs - even if Labour need their votes to secure its passage
VE Day 70th anniversary: How ordinary Britons celebrated the end of war in Europe

How ordinary Britons celebrated VE Day

Our perception of VE Day usually involves crowds of giddy Britons casting off the shackles of war with gay abandon. The truth was more nuanced
They came in with William Caxton's printing press, but typefaces still matter in the digital age

Typefaces still matter in the digital age

A new typeface once took years to create, now thousands are available at the click of a drop-down menu. So why do most of us still rely on the old classics, asks Meg Carter?
Discovery of 'missing link' between the two main life-forms on Earth could explain evolution of animals, say scientists

'Missing link' between Earth's two life-forms found

New microbial species tells us something about our dark past, say scientists
The Pan Am Experience is a 'flight' back to the 1970s that never takes off - at least, not literally

Pan Am Experience: A 'flight' back to the 70s

Tim Walker checks in and checks out a four-hour journey with a difference
Humans aren't alone in indulging in politics - it's everywhere in the animal world

Humans aren't alone in indulging in politics

Voting, mutual back-scratching, coups and charismatic leaders - it's everywhere in the animal world
Crisp sales are in decline - but this tasty trivia might tempt back the turncoats

Crisp sales are in decline

As a nation we're filling up on popcorn and pitta chips and forsaking their potato-based predecessors
Ronald McDonald the muse? Why Banksy, Ron English and Keith Coventry are lovin' Maccy D's

Ronald McDonald the muse

A new wave of artists is taking inspiration from the fast food chain
13 best picnic blankets

13 best picnic blankets

Dine al fresco without the grass stains and damp bottoms with something from our pick of picnic rugs
Barcelona 3 Bayern Munich 0 player ratings: Lionel Messi scores twice - but does he score highest in our ratings?

Barcelona vs Bayern Munich player ratings

Lionel Messi scores twice - but does he score highest in our ratings?
Martin Guptill: Explosive New Zealand batsman who sets the range for Kiwis' big guns

Explosive batsman who sets the range for Kiwis' big guns

Martin Guptill has smashed early runs for Derbyshire and tells Richard Edwards to expect more from the 'freakish' Brendon McCullum and his buoyant team during their tour of England
General Election 2015: Ed Miliband's unlikely journey from hapless geek to heart-throb

Miliband's unlikely journey from hapless geek to heart-throb

He was meant to be Labour's biggest handicap - but has become almost an asset
General Election 2015: A guide to the smaller parties, from the the National Health Action Party to the Church of the Militant Elvis Party

On the margins

From Militant Elvis to Women's Equality: a guide to the underdogs standing in the election
Amr Darrag: Ex-Muslim Brotherhood minister in exile still believes Egypt's military regime can be replaced with 'moderate' Islamic rule

'This is the battle of young Egypt for the future of our country'

Ex-Muslim Brotherhood minister Amr Darrag still believes the opposition can rid Egypt of its military regime and replace it with 'moderate' Islamic rule, he tells Robert Fisk
Why patients must rely less on doctors: Improving our own health is the 'blockbuster drug of the century'

Why patients must rely less on doctors

Improving our own health is the 'blockbuster drug of the century'